Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Larotrectinib Sulfate

FDA-approved product (capsule, oral), marketed as Vitrakvi.

Registered studies
5
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Larotrectinib Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abdominal Neoplasms
  • Cancer
  • Metastasis
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Larotrectinib Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Larotrectinib Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

    NCT04879121 · start 2021-04-30

    Registered record
    Registry ID
    NCT04879121
    Conditions
    Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
    Interventions
    Larotrectinib Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-04-30
    Completion
    2027-11-11
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
    InterventionLarotrectinib Sulfate
    PhasePhase 2
    Registry statusRecruiting

  • Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

    NCT03834961 · start 2019-10-25

    Registered record
    Registry ID
    NCT03834961
    Conditions
    Central Nervous System Neoplasm; Infantile Fibrosarcoma; Recurrent Acute Leukemia; Refractory Acute Leukemia; Solid Neoplasm
    Interventions
    Larotrectinib Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-10-25
    Completion
    2027-07-25
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Nervous System Neoplasm; Infantile Fibrosarcoma; Recurrent Acute Leukemia; Refractory Acute Leukemia +1 more
    InterventionLarotrectinib Sulfate
    PhasePhase 2
    Registry statusActive not recruiting

  • Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

    NCT03213704 · start 2017-08-23

    Registered record
    Registry ID
    NCT03213704
    Conditions
    Advanced Malignant Solid Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoi
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan; Computed Tomography; Larotrectinib Sulfate; Magnetic Resonance Imaging; Radionuclide Imaging; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-08-23
    Completion
    2026-10-08
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma +27 more
    InterventionBiospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan; Computed Tomography +4 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

    NCT03155620 · start 2017-07-31

    Registered record
    Registry ID
    NCT03155620
    Conditions
    Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphom
    Interventions
    Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan; Computed Tomography; Ensartinib; Erdafitinib; Ivosidenib; Laboratory Biomarker Analysis; Larotrectinib Sulfate; Magnetic Resonance Imaging; Mutation Carrier Screening; Olaparib; Palbociclib; Pharmacological Study; Positron Emission Tomography; Radionuclide Imaging; Samotolisib; Selpercatinib; Selumetinib Sulfate; Tazemetostat; Tipifarnib; Ulixertinib; Vemurafenib; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-07-31
    Completion
    2027-01-06
    Enrolment
    1,377

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma +28 more
    InterventionBiopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan +21 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    NCT02465060 · start 2015-08-17

    Registered record
    Registry ID
    NCT02465060
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
    Interventions
    Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-17
    Completion
    2026-12-31
    Enrolment
    6,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 more
    InterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 more
    PhasePhase 2
    Registry statusActive not recruiting